SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Procept (PRCT): 50% rise on high volume. Why?
PRCT 30.75-1.8%Nov 12 3:59 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Gerald Thomas who wrote (77)4/6/1997 3:30:00 PM
From: Douglas   of 455
 
You were correct. The agency in Britain is the British Medical Research Council. I hope Procept is successful.

I was reviewing the Gilead(GILD) product Forvade(cidofovir gel). In January of this year, GILD filed a new drug application to market Forvade to treat refractory herpes simplex virus infection in patients with AIDS. They are in phase I/II human clinical studies of Forvade for the potential treatment of genital warts caused by human papillomarvirus in patients infected with HIV and in phase I/II for recurrent genital herpes. I found no mention of the development of microbicides to prevent the sexual transmission of HIV in healthy humans. I'm not certain that they are pursuing this market (prevention). The worldwide demand for such a product should be extremely large. I like the idea of Procept and the British working together. This gives Procept a potential foothold in the European market.

Abstract #343 of the 4th Conference on Retroviruses and Opportunistic Infections mentions that the Centre de Recherche en Infectiologie of Quebec was developing a microbicide to prevent the sexual transmission of HIV. No mention of the name of their product.

Gilead has an FDA approved drug Vistide for the treatment of CMV Retinitis. Vistide is an cidofovir injection. Forvade is an cidofovir gel. Your right about PRO 2000-that was an injection. Promising results of the systemic trial would have a positive impact on their stock price. A company needs more than one product!
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News